Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for feline patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Journal of veterinary internal medicine in 2026 evaluated effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats..
Key Findings
Erythropoietic effects of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, occur in anemic cats with chronic kidney disease (CKD). To evaluate the effectiveness and safety of molidustat in managing anemia in cats with CKD. Seventy-five client-owned anemic cats with CKD in the effectiveness and safety phase and 64 in the safety continuation phase. Multicenter, randomized, double-masked, placebo-controlled field study. Cats in the 28-day effectiveness and safety phase received 5 mg/kg of molidustat (n = 40) or a control product (CP; n = 35), once daily for 28 days. During the 20-week safety continuation phase, all cats...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for feline patients.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
List
Add
Please enter a comment